Form 4: Vir Biotechnology EVP Vanina de Verneuil Sells Shares to Cover Tax Obligations and Under 10b5-1 Plan

Vanina de Verneuil, EVP and General Counsel of Vir Biotechnology, sold shares to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

Summary

• Vanina de Verneuil, EVP and General Counsel of Vir Biotechnology, sold 1,403 shares of common stock on November 1, 2024, at a price of $7.2039 per share.
• She also sold 2,347 shares on November 5, 2024, at a weighted average price of $9.4696 per share, with prices ranging from $9.30 to $9.62.
• These sales were executed to cover tax withholding obligations related to the vesting of restricted stock units and under a Rule 10b5-1 trading plan adopted on August 5, 2024.
• Following these transactions, de Verneuil directly owns 61,370 shares of Vir Biotechnology common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales by an executive, which are part of normal business operations and pre-planned.

Industry Context

Sales by company executives are a common occurrence and are often related to personal financial planning or tax obligations. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices, avoiding accusations of insider trading.

Stakeholder Impact

• The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates